[go: up one dir, main page]

SV2016005214A - Sistema de administración farmacológico - Google Patents

Sistema de administración farmacológico

Info

Publication number
SV2016005214A
SV2016005214A SV2016005214A SV2016005214A SV2016005214A SV 2016005214 A SV2016005214 A SV 2016005214A SV 2016005214 A SV2016005214 A SV 2016005214A SV 2016005214 A SV2016005214 A SV 2016005214A SV 2016005214 A SV2016005214 A SV 2016005214A
Authority
SV
El Salvador
Prior art keywords
thermoplastic polymer
administration system
therapeutic
agent
pharmacological administration
Prior art date
Application number
SV2016005214A
Other languages
English (en)
Inventor
Willy J H Verhoeven
Graaff Wouter De
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SV2016005214A publication Critical patent/SV2016005214A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EN EL PRESENTE DOCUMENTO SE DESCRIBE UN SISTEMA DE ADMINISTRACIÓN FARMACOLÓGICO INTRAVAGINAL QUE COMPRENDE (I) UN NÚCLEO QUE COMPRENDE UN PRIMER POLÍMERO TERMOPLÁSTICO Y UN PRIMER AGENTE TERAPÉUTICO, EN EL QUE EL PRIMER AGENTE TERAPÉUTICO SE DISUELVE EN EL PRIMER POLÍMERO TERMOPLÁSTICO, Y (II) UNA CAPA EXTERNA QUE RODEA EL NÚCLEO QUE COMPRENDE UN SEGUNDO POLÍMERO TERMOPLÁSTICO, EN EL QUE EL PRIMER AGENTE TERAPÉUTICO ES MENOS PERMEABLE EN EL SEGUNDO POLÍMERO TERMOPLÁSTICO QUE EL PRIMER POLÍMERO TERMOPLÁSTICO, Y UN SEGUNDO AGENTE TERAPÉUTICO EN FORMA SÓLIDA, EN EL QUE EL SEGUNDO AGENTE TERAPÉUTICO ESTÁ CARGADO EN UNA PORCIÓN DE LA CAPA EXTERNA
SV2016005214A 2013-12-11 2016-06-10 Sistema de administración farmacológico SV2016005214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914500P 2013-12-11 2013-12-11
EP13196737 2013-12-11

Publications (1)

Publication Number Publication Date
SV2016005214A true SV2016005214A (es) 2016-11-21

Family

ID=49759119

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005214A SV2016005214A (es) 2013-12-11 2016-06-10 Sistema de administración farmacológico

Country Status (23)

Country Link
US (1) US10413504B2 (es)
EP (1) EP3079660B1 (es)
JP (1) JP6251396B2 (es)
KR (1) KR101808977B1 (es)
CN (1) CN105979930B (es)
AP (1) AP2016009223A0 (es)
AU (1) AU2014363724B2 (es)
BR (1) BR112016013325B1 (es)
CA (1) CA2931559C (es)
CR (1) CR20160261A (es)
DO (1) DOP2016000132A (es)
EA (1) EA031802B1 (es)
HK (1) HK1224208A1 (es)
IL (1) IL245544A0 (es)
MA (1) MA39059A1 (es)
MD (1) MD20160079A2 (es)
MX (1) MX2016007681A (es)
PE (1) PE20160680A1 (es)
PH (1) PH12016501083A1 (es)
SG (1) SG11201604660VA (es)
SV (1) SV2016005214A (es)
TW (1) TW201607563A (es)
WO (1) WO2015086491A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
WO2015094758A1 (en) 2013-12-19 2015-06-25 The Procter & Gamble Company Shaping keratin fibres using an active agent comprising a functional group selected from the group consisting of: -c(=o)-, -c(=o)-h, and -c(=o)-o-
US11110046B2 (en) 2013-12-19 2021-09-07 The Procter And Gamble Company Shaping keratin fibres using 2-hydroxypropane-1,2,3-tricarboxylic acid and/or 1,2,3,4-butanetetracarboxylic acid
WO2015094838A1 (en) 2013-12-19 2015-06-25 The Procter & Gamble Company Shaping keratin fibres using a reducing composition and a fixing composition
CN105828793B (zh) 2013-12-19 2019-06-18 宝洁公司 使用糖使角蛋白纤维成形
MX353843B (es) 2013-12-19 2018-01-30 Procter & Gamble Modelado de fibras de queratina con el uso de ácido oxoetanoico y/o derivados de este.
EP3082731B1 (en) 2013-12-19 2018-07-04 The Procter and Gamble Company Shaping keratin fibres using an active agent comprising at least two functional groups selected from: -c(oh)- and -c(=o)oh
WO2015094837A1 (en) 2013-12-19 2015-06-25 The Procter & Gamble Company Shaping keratin fibres using carbonate ester
EP3017809A1 (en) * 2014-11-07 2016-05-11 Ferring B.V. Drug-device unit containing quinagolide
MX2017008203A (es) 2014-12-19 2017-10-06 Procter & Gamble Metodo para dar forma a fibras de queratina.
WO2016100257A1 (en) 2014-12-19 2016-06-23 The Procter & Gamble Company Shaping keratin fibres using arabinose and ethylene carbonate
MX2017016152A (es) 2015-06-18 2018-04-18 Procter & Gamble Modelado de fibras de queratina mediante el uso de compuestos de dialdehido.
CN108135836A (zh) * 2015-08-11 2018-06-08 Ptt控股公司 递送装置
EP3395335A1 (en) * 2017-04-24 2018-10-31 Kern Pharma, S.L. Vaginal ring for the simultaneous release of two active ingredients
DE102017113166A1 (de) * 2017-06-14 2018-12-20 Amw Gmbh Depotform zur Abgabe eines Östrogen-Wirkstoffs
BR112020023982A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4215180A1 (en) * 2022-01-21 2023-07-26 Sever Pharma Solutions A drug delivery system
EP4465939A4 (en) * 2022-01-21 2026-01-07 The Population Council Inc Intravaginal Combination Therapy Rings
EP4626399A1 (en) 2022-12-02 2025-10-08 VaRi Bioscience GmbH Estriol vaginal ring

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US4237885A (en) 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
EP0162492B1 (en) 1984-04-11 1989-08-02 Thiemann Arzneimittel GmbH Dosage units for controlled release of active material
EP0180264A1 (en) 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
ES2054784T3 (es) 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
AU3432689A (en) 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
JP3720386B2 (ja) 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
EP0836473B1 (en) 1995-07-04 2001-10-31 Akzo Nobel N.V. Ring-shaped devices
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
TW358031B (en) 1997-04-11 1999-05-11 Akze Nobel N V Drug delivery system for 2 or more active substances
CA2313196C (en) 1997-12-12 2006-07-11 Akzo Nobel Nv A package for a vaginal ring
CA2315103A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
US6579533B1 (en) 1999-11-30 2003-06-17 Bioasborbable Concepts, Ltd. Bioabsorbable drug delivery system for local treatment and prevention of infections
IL157771A0 (en) 2001-03-27 2004-03-28 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
EP1408876A4 (en) 2001-06-22 2004-09-22 Durect Corp ZERO ORDER COAXIAL IMPLANTS WITH EXTENDED RELEASE
AU2002313517B2 (en) 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
CN1596104A (zh) 2001-09-28 2005-03-16 麦克内尔-Ppc股份有限公司 改进的释放剂型
CN1242819C (zh) 2002-06-07 2006-02-22 上海市计划生育科学研究所 一种新型阴道环及制备方法
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
WO2005004837A1 (en) 2003-07-10 2005-01-20 Galen (Chemicals) Limited Intravaginal drug delivery devices
WO2005030175A1 (en) * 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Hrt formulations
JP2007530500A (ja) * 2004-03-24 2007-11-01 ナームローゼ・フエンノートチヤツプ・オルガノン ポリエチレン酢酸ビニル共重合体に基づく薬物送達システム
KR20060046263A (ko) * 2004-08-04 2006-05-17 도쿄파츠고교 가부시키가이샤 편평형 진동모터를 내장시킨 전자음향변환기
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
EP2097063B1 (en) 2006-11-20 2013-08-07 Intervet International B.V. Helically-shaped drug delivery system
US10258571B2 (en) 2007-02-12 2019-04-16 Particle Sciences, Inc. Delivery devices containing encapsulated and/or practice-bound active pharmaceutical ingredients
PE20081895A1 (es) 2007-03-26 2009-01-26 Theramex Regimen anticonceptivo oral
KR101696301B1 (ko) 2007-09-07 2017-01-13 마티 테라퓨틱스 인코포레이티드 치료 약제의 서방성 약물 코어
TW200930343A (en) 2007-09-21 2009-07-16 Organon Nv Drug delivery system
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
MX2012000948A (es) 2009-07-21 2012-02-28 Population Council Inc Anillo vaginal gradiente multicapas.
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
TW201332585A (zh) 2012-02-14 2013-08-16 Chemo Res S L 核鞘藥物遞送裝置
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
IL245544A0 (en) 2016-06-30
DOP2016000132A (es) 2016-07-31
CA2931559A1 (en) 2015-06-18
US20150157561A1 (en) 2015-06-11
EA201691193A1 (ru) 2016-09-30
SG11201604660VA (en) 2016-07-28
KR20160095110A (ko) 2016-08-10
BR112016013325A2 (es) 2017-08-08
PH12016501083A1 (en) 2016-07-25
CN105979930B (zh) 2019-11-19
MD20160079A2 (ro) 2016-10-31
TW201607563A (zh) 2016-03-01
KR101808977B1 (ko) 2017-12-13
AU2014363724B2 (en) 2017-02-23
EP3079660B1 (en) 2021-03-03
JP6251396B2 (ja) 2017-12-20
JP2016539991A (ja) 2016-12-22
AU2014363724A1 (en) 2016-05-26
CR20160261A (es) 2016-08-16
AP2016009223A0 (en) 2016-05-31
PE20160680A1 (es) 2016-07-31
CN105979930A (zh) 2016-09-28
MX2016007681A (es) 2016-10-14
HK1224208A1 (zh) 2017-08-18
BR112016013325B1 (pt) 2022-11-29
WO2015086491A1 (en) 2015-06-18
EP3079660A1 (en) 2016-10-19
MA39059A1 (fr) 2018-08-31
CA2931559C (en) 2018-03-13
EA031802B1 (ru) 2019-02-28
US10413504B2 (en) 2019-09-17

Similar Documents

Publication Publication Date Title
SV2016005214A (es) Sistema de administración farmacológico
BR112016012615A8 (pt) sistemas, e kit
CR20140487A (es) Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo
MX2015012367A (es) Dispositivos de suministro de farmacos con un componente permeable al farmaco y metodos.
PE20150093A1 (es) Tuberia multicapa de material polimero, dispositivo para la fabricacion de tuberias multicapa y metodo para fabricar tuberias multicapa
AR081113A1 (es) Liberacion pulsatil de medicamentos desde un tapon de punctum
CL2015002926A1 (es) Método de fabricación de la espuma absorbente de material compuesto.
CL2015001882A1 (es) Sistema de entrega de fragancias
SE1650380A1 (sv) Oxygen barrier film and laminate and methods of manufacturing the same
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
PA8815901A1 (es) Sistema de administracion de drogas con efecto estabilizante
BR112013024585A8 (pt) formas de dosagem farmacêutica de liberação controlada
AR093411A1 (es) Metodos para formar y colocar pilares de soporte en una formacion subterranea
PE20170995A1 (es) Aposito laminado de espuma
MX2015017979A (es) Sistema de emanacion y metodo de uso.
CR20150414A (es) Tubo extrudible multicapa
DOP2016000024A (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
MX2020003662A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.
CU20150142A7 (es) Método y sistema para la fabricación de artículos alargados de concreto
CL2015003779A1 (es) Dispositivo de oclusión con via abierta.
AR098129A1 (es) Preparación y administración de soluciones de liberación sostenida de óxido nítrico
MX2015008525A (es) Material polimerico celular.
BR112017011433A2 (pt) roda abrasiva não tecida com uma camada de barreira à umidade
AR098757A1 (es) Método para preparar una película pre-estirada